| Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type | Phase 3 | Suven Life Sciences Limited | <1 mi |
| Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3) | — | University of Southern California | <1 mi |
| A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004) | Phase 2 | Merck Sharp & Dohme LLC | <1 mi |
| A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) | Phase 3 | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | <1 mi |
| Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3) | Phase 3 | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | <1 mi |
| A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease | Phase 3 | Hoffmann-La Roche | <1 mi |
| A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD | Phase 3 | Annovis Bio Inc. | <1 mi |
| A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam) | Phase 2 | Alzheimer's Disease Cooperative Study (ADCS) | <1 mi |
| Longitudinal Early-onset Alzheimer's Disease Study Protocol | — | Indiana University | <1 mi |
| A Dyadic Sleep Health Approach for Persons With Alzheimer's Disease and Caregivers | N/A | University of California, Los Angeles | <1 mi |
| Deep Repetitive Transcranial Magnetic Stimulation (rTMS) of the Precuneus for Alzheimer Disease (AD) | Phase 1/2 | University of California, Los Angeles | <1 mi |
| A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease | Phase 2 | Novartis Pharmaceuticals | <1 mi |
| [18F]PI-2620 Phase 3 Histopathological Study | Phase 3 | Life Molecular Imaging Ltd | <1 mi |
| Testing & Refinement of CarePair: An Assessment and Referral Platform to Support Family Caregivers of Alzheimer's Disease and Related Dementias. | N/A | University of Southern California | <1 mi |
| Transcranial Photobiomodulation (tPBM) in Alzheimer's Disease Study | N/A | Cedars-Sinai Medical Center | <1 mi |
| Repurposing Nucleoside Reverse Transcriptase Inhibitors for Treatment of AD | Phase 1 | Butler Hospital | <1 mi |
| Polyphenols and Cognitive Decline | N/A | University of California, Los Angeles | <1 mi |
| Low Intensity Focused Ultrasound for Mild Cognitive Impairment and Mild Alzheimer's Disease | N/A | University of California, Los Angeles | <1 mi |
| Cardiac-Control Affecting Learning Through Mindfulness (CALM) | N/A | University of Southern California | <1 mi |
| Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant | Phase 3 | Eidos Therapeutics, a BridgeBio company | <1 mi |
| Music-Based Interventions, Aging, Alzheimer's Disease | N/A | University of Southern California | <1 mi |
| Senicapoc in Alzheimer's Disease | Phase 2 | University of California, Davis | <1 mi |
| Effect of LEQEMBI on Cerebral and Retinal Amyloid in Mild Cognitive Impairment Due to Alzheimer's Disease | — | NeuroVision Imaging | <1 mi |
| Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers | Phase 1/2 | Ashvattha Therapeutics, Inc. | <1 mi |
| Remotely-supervised Neuromodulation in PPA | N/A | University of Texas at Austin | <1 mi |
| Characterizing Cognitive Decline in Late Life Depression: The ADNI Depression Project | — | University of Southern California | <1 mi |
| Study of Biodistribution, Metabolism, Excretion and Brain Uptake 18F-JSS20-183A | Early 1 | University of Pennsylvania | <1 mi |
| First-in-Human Evaluation of an Astrocytic Glutamate Transporter (EAAT2) PET Tracer in Dementia | Phase 1/2 | David Wilson | <1 mi |
| A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) | Phase 3 | Bristol-Myers Squibb | <1 mi |
| A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2) | Phase 3 | Bristol-Myers Squibb | <1 mi |
| A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2) | Phase 3 | Bristol-Myers Squibb | <1 mi |
| A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis | Phase 2 | MapLight Therapeutics | <1 mi |
| Promoting Physical Activity in Older Hispanic/Latino(a) Adults | N/A | Kaiser Permanente | <1 mi |
| Alzheimer Prevention Trials (APT) Webstudy | — | University of Southern California | <1 mi |
| TREAD: Time Restricted Eating Intervention for Alzheimer's Disease | Phase 1 | University of California, San Diego | <1 mi |
| Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies | Phase 3 | Hoffmann-La Roche | <1 mi |
| A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease | Phase 3 | Hoffmann-La Roche | <1 mi |
| A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease | Phase 3 | Bristol-Myers Squibb | <1 mi |
| ACP-204 in Adults With Alzheimer's Disease Psychosis | Phase 2/3 | ACADIA Pharmaceuticals Inc. | 1 mi |
| Clinical Study of SNK01 in Participants With Moderate Alzheimer's Disease | Phase 1/2 | NKGen Biotech, Inc. | 6 mi |
| Open-Label Extension Protocol to SNK01-AD01 Study | Phase 2 | NKGen Biotech, Inc. | 6 mi |
| Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease | Phase 2 | Celgene | 7 mi |
| A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease | Phase 2 | Intra-Cellular Therapies, Inc. | 7 mi |
| Allopregnanolone Regenerative Therapeutic for Mild Alzheimer's Disease | Phase 2 | University of Arizona | 7 mi |
| A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD) | Phase 1 | Eli Lilly and Company | 7 mi |
| A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1) | Phase 3 | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | 9 mi |
| Mesenchymal Stem Cells for the Treatment of Various Chronic and Acute Conditions | Phase 1/2 | Thomas Advanced Medical LLC | 9 mi |
| A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1) | Phase 3 | Bristol-Myers Squibb | 10 mi |
| Computerized Tests of Cognitive Decline in Presymptomatic Alzheimer's Disease | N/A | Neurobehavioral Systems, Inc. | 10 mi |
| A Clinical Trial of AAV2-BDNF Gene Therapy in Early Alzheimer's Disease and Mild Cognitive Impairment | Phase 1 | Mark Tuszynski | 11 mi |
| Is Obstructive Sleep Apnea Important in the Development of Alzheimer's Disease? | Phase 1 | University of California, San Diego | 11 mi |
| A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation | Phase 2/3 | Washington University School of Medicine | 11 mi |
| A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD | Phase 1 | Alnylam Pharmaceuticals | 11 mi |
| A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation | Phase 2/3 | Washington University School of Medicine | 11 mi |
| FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases | — | xCures | 13 mi |
| A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008) | Phase 2 | Merck Sharp & Dohme LLC | 14 mi |
| A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia | Phase 2 | Intra-Cellular Therapies, Inc. | 15 mi |
| Door-Through-Door Companion Rideshare Technology for Individuals With Alzheimer's Disease and Related Dementias (AD/ADRD) | Phase 1 | Onward Health, Inc | 15 mi |
| An Objective Assessment Tool for Evaluating Functioning in Older Adults | — | Stanford University | 16 mi |
| Assessing Cognitive Decline at Home | — | Stanford University | 16 mi |
| Sleep Disturbance and Emotion Regulation Brain Dysfunction as Mechanisms of Neuropsychiatric Symptoms in Alzheimer's Dementia | N/A | Stanford University | 16 mi |
| Bumetanide in Patients With Alzheimer's Disease | Phase 2 | Stanford University | 17 mi |
| A Phase Ia/Ib, First-in-human (FIH) Study for Safety, Tolerability, Pharmacokinetics (PK), and Clinical Activity Evaluation of ADEL-Y01 | Phase 1 | Alzheimer's Disease Expert Lab (ADEL), Inc. | 17 mi |
| Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease | Phase 1 | Regeneration Biomedical, Inc. | 19 mi |
| Evaluating Novel Healthcare Approaches to Nurturing and Caring for Hospitalized Elders | N/A | University of Michigan | 20 mi |
| Trial-Ready Cohort-Down Syndrome (TRC-DS) | — | University of Southern California | 20 mi |
| Biomarker Exploration in Aging, Cognition and Neurodegeneration | Phase 3 | University of California, Irvine | 22 mi |